Recent Events
Conference Details
Second Annual Exploratory Clinical Development Congress
Brief Description: Conference Highlights Exploratory clinical development remains at critical stage in the drug development process. The transition to first in man has crucial regulatory, scientific and operational issues that need to confronted head on in order to avoid early on can result it high costs and high profile product failures.
The second annual Exploratory Clinical Development Congress will address the critical issues in achieving seamless first in man studies and will also provide advice on how to conduct effective studies that allow you to make the right decision early on in clinical development.
- A timely update on the guidance for first man studies the revision of EMEA guidelines
- What are the challenges and priorities over the next five years for the MHRA
- How to manage potentially 'high risk' complex molecules. Tegenero: a case study
- The challenges of conducting phase I studies in patients
Date: May 14-15, 2008
Location: Earl's Court Conference Centre, London
Stand Number: TBC
Conference Details
17th Annual Partnerships with CROs
Brief Description: Partnerships with CROs has set the standard in outsourcing and clinical development conferences. The clinical development and outsourcing industry's most widely attended and well respected event delivers information and strategies you can put to work.
Date: April 14 - 18, 2008
Location: Mandalay Bay, Las Vegas, USA
Stand Number: TBC
Conference Details
ACDM Annual Conference - Climate Change
Brief Description: The day to day operational climate for the Data Manager continues to change, Globalisation, increasing commercial pressures, evolving standards and new technologies, are but a few of the challenges the industry continues to face. Data Managers have successfully embraced many similar challenges over the past two decades and have become very adept in coping in rapidly changing environment.
The 2008 Conference brings an exciting mix of presentation and discussion where a number of contributors will share their experiences and how they are adapting their business process in this dynamic environment.
The agenda has been designed with topics of interest for data managers that are new to the profession as well as those more experienced data managers. The conference will include a range of exhibitors and there are sponsorship opportunities available.
Date: March 31 April 1, 2008
Location: Whittlebury Hall Hotel, Northamptonshire
Stand Number: TBC
Conference Details
QT Prolongation and Safety Pharmacology
Brief Description: Key presentations:
- Clobutinol (Silomat or Lomisat), a drug voluntarily withdrawn from the market because of proarrhythmic risk
- Implementation of the ICH E14 guideline
- The Japanese Pharmaceutical and Medical Devices Agency's view on safety issues
- Cardiac safety for oncology compounds
- Efficient design of Thorough QT studies
- Efficacy and cost effectiveness of clinical Thorough QT studies
- Clinical aspects of short QT syndrome
Date: March 18 - 19, 2008
Location: Paris Rive Gauche Hotel & Conference Center (MARRI), Paris, France
Stand Number: TBC
Conference Details
23rd Annual DIA Conference and Exhibition: Data Management in Transition: Putting the "e" in Data Management
Brief Description: Following the success of last years conference, this years conference will again feature expanded tracks and sessions on data management and eClinical topics.
This conference will feature tutorials, tracks, and sessions that target both the beginner and intermediate/advanced level clinical data management professional. Other highlights will include a Keynote Speaker, FDA Update & Town Hall plenary session, and a Networking Reception.
Date: March 16 - 18, 2008
Location: JW Marriott Hotel, Washington DC, USA
Stand Number: TBC
Conference Details
9th Annual Phase I Clinical Trials: Improving safety, reducing costs and increasing efficiency in Phase I studies
Brief Description: Conference Highlights
- A timely update on the guidance for first man studies the revision of EMEA guidelines
- What are the challenges and priorities over the next five years for the MHRA
- How to manage potentially high risk complex molecules. Tegenero: a case study
- The challenges of conducting phase I studies in patients
Date: February 19-20, 2008
Location: Olympia Conference Centre, London
Stand Number: TBC
Conference Details
Clinical Outsourcing Congress
Brief Description: Outsourcing remains a critical aspect of clinical development. All major drug development projects rely on one or more partners to aid the passage of successful therapeutics to the market, whilst terminating failing compounds early.
The question now is not whether to outsource but which part of your development programme should you outsource and how do you outsource efficiently?
The Clinical Outsourcing Congress addresses the major strategic and operational issues involved in outsourcing. Issues to be addressed include:
- Assessing the true value of clinical outsourcing
- How do you identify your core competencies?
- How do you develop an operational culture that embraces outsourcing?
- Partnering with niche providers
- Improving the speed and quality of clinical trials
- Managing long and short term contracts
- Measuring and reducing risk
- Clinical trials in low cost countries
Date: January 30 - 31, 2008
Location: Earl's Court Conference Centre, London
Stand Number: Associate Sponsor
Conference Details
2nd Cardiac Safety Conference
Brief Description: ICH E14 QT Guidance were finalised (step 4) in May 2005. However, implementation of the new guidance (step 5) seems to have taken a different pace in different ICH regions, with US FDA leading the trend and Japan PMDA still developing their own version. The controversy regarding the predictive value of different non-clinical and clinical QT assays (including the TQT study itself) continue to underline the regional regulatory variations. As global experience is building up, Thorough QT (TQT) study designs are improving, sample size dropping and the use of positive control(s) becoming more sophisticated. The potential benefits of capturing and viewing multidimensional aspects of continuous QT and morphology data are gathering momentum with innovative technologies and methodologies coming up. Analysing and reporting QT data is also evolving while various TQT outcome scenarios are emerging. Concentration-effect modelling, promoted by US FDA, is increasingly taking a central role in the analysis and reporting of QT data. At the same time certain therapeutic classes, such as oncology and biological products, are still cast with uncertainty and face inconsistent regulatory requirements in the various regions.
At the other end of the drug development spectrum, ongoing issues involving post marketing pharmacovigilance continue to make headlines. Cardiac Adverse Reactions, whether repolarisation-based, thrombosis-related or other are reported increasingly, involving a variety of drug classes. While legal and financial liabilities are still strong driving forces for cardiac safety pharmacovigilance, new public and regulatory initiatives are endorsing more proactive risk management and risk minimisation plans. These topics and others will be interactively discussed during the conference.
Date: December 3 - 4, 2007
Location: Dorint Praha Don Giovanni Hotel, Prague, Czech Republic
Stand Number: 4
Conference Details
6th Annual Partnerships in Clinical Trials
Book via Richmond Pharmacology and receive a 25% discount on the delegate fee!
To register and receive a 25% discount, please visit the website and enter VIP Code CQ3002RIC
Brief Description: Richmond Pharmacology will be exhibiting at the Partnerships in Clinical Trials Conference, the largest gathering of clinical trials outsourcing professionals in Europe. For full details of the Conference Programme please visit the CTC website.
Date: November 5-8, 2007
Location: Amsterdam RAI, the Netherlands
Stand Number: 15 - stop by to enter this years' most exciting prize draw to win a trip to New York!
Conference Details
QT and Drug Development
Brief Description: Cardiovascular adverse effects continue to dominate the industry agenda. A well designed and executed QTc study has the potential to characterise pro-arrythmic risk of products in development. This major conference will bring together industry, regulators and academic bodies to discuss the scientific and regulatory challenges in QT analysis and reporting. Topics to be addressed include:
- Regulatory and Industry review of S7 and E14 guidelines
- Selecting predictable preclinical assays
- Preclinical safety testing strategies
- Conduct and design of a TQT Study
- Integrating preclinical and clinical data
- QT labelling
- ECG in clinical safety evaluation
- Exposure QT modelling
Date: October 24 - 25, 2007
Location: Copthorne Tara Hotel, London
Stand Number: Associate Sponsor
Conference Details
The Pharma-Bio Outsourcing Conference and Exhibition
Brief Description: This event will address the fundamental questions in the rapidly evolving world of outsourcing in global pharmaceutical research and development.
Date: July 10 - 11, 2007
Location: Savoy Place, London
Additional Info: The Managing Director, Dr Jorg Taubel will be talking about Early Phase Medical Trials at the event.
Stand Number: TBC
Conference Details
The second Club Phase I and AGAH Joint Annual Meeting
Brief Description: This second joint meeting of Club Phase I, the French association of Early Drug Development, and AGAH, the German association of Applied Human Pharmacology, addresses vital issues such as: how to position human pharmacology for the future and which role should human pharmacology play in the development of new classes of drugs.
Date: April 26 - 27, 2007
Location: Bad Homburg, Germany
Stand Number: 18
Conference Details
16th Annual Partnerships with CRO’s Conference
Brief Description: This outsourcing and clinical development conference will address the relationships between Clinical Research Organisations that bring critical therapies to patients who need them the most safely and efficiently.
Date: April 10 - 12, 2007
Location: Orlando, USA
Stand Number: 614
